Filing Details
- Accession Number:
- 0001209191-21-008660
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-08 21:00:22
- Reporting Period:
- 2021-02-04
- Accepted Time:
- 2021-02-08 21:00:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1432545 | R. Srdjan Stankovic | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-02-04 | 19,231 | $0.00 | 39,478 | No | 4 | A | Direct | |
Common Stock | Disposition | 2021-02-04 | 8,429 | $50.61 | 31,049 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Acquisiton | 2021-02-04 | 15,625 | $0.00 | 15,625 | $29.59 |
Common Stock | Employee Stock Option (Right to Buy) | Acquisiton | 2021-02-04 | 21,875 | $0.00 | 21,875 | $35.80 |
Common Stock | Employee Stock Option (Right to Buy) | Acquisiton | 2021-02-04 | 11,875 | $0.00 | 11,875 | $21.28 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
15,625 | 2027-08-03 | No | 4 | A | Direct | |
21,875 | 2027-09-07 | No | 4 | A | Direct | |
11,875 | 2028-10-15 | No | 4 | A | Direct |
Footnotes
- On April 29, 2019, the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above.
- The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 15,625 shares.
- On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 21,875 shares.
- On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 11,875 shares.